LAB files 8-K with Q3 and nine-month 2025 results, outlook

Rhea-AI Filing Summary

Standard BioTools Inc. furnished an 8-K announcing it issued a press release with selected financial results for the three and nine months ended September 30, 2025. The release is attached as Exhibit 99.1.

Sections titled “Operational Restructuring” and “Full Year 2025 Revenue Outlook,” along with the forward-looking statement disclaimer, are furnished under Regulation FD. The information in Items 2.02 and 7.01, including Exhibit 99.1, is expressly furnished and not deemed filed under the Exchange Act.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001162194 false00011621942025-11-042025-11-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November 4, 2025

Standard BioTools Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)	001-34180 (Commission File Number)	77-0513190 (I.R.S. Employer Identification Number)
2 Tower Place, Suite 2000 South San Francisco, California 94080
(Address of principal executive offices and zip code)
(650) 266-6000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class		Trading Symbol		Name of each exchange on which registered
Common stock, $0.001 par value per share		LAB		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 - Results of Operations and Financial Condition

On November 4, 2025, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three and nine months ended September 30, 2025. The press release is attached hereto as Exhibit 99.1.

The information set forth in the press release, except for the information set forth under the headings “Operational Restructuring,” “Full Year 2025 Revenue Outlook” and “About Standard BioTools Inc.,” together with the forward-looking statement disclaimer, is incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.

Item 7.01. Regulation FD Disclosure.

The information set forth under the headings “Operational Restructuring,” “Full Year 2025 Revenue Outlook” and “About Standard BioTools Inc.,” together with the forward-looking statement disclaimer, is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by Standard BioTools Inc., dated November 4, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

The information in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Date:		November 4, 2025
	STANDARD BIOTOOLS INC.
	By:		/s/ Alex Kim
	Name:		Alex Kim
	Title:		Chief Financial Officer
			(Principal Financial and Accounting Officer)

FAQ

What did Standard BioTools (LAB) announce in this 8-K?

The company furnished a press release with financial results for the three and nine months ended September 30, 2025, attached as Exhibit 99.1.

Which periods are covered by the results for LAB?

The press release includes results for the three and nine months ended September 30, 2025.

What additional topics are included for LAB in this disclosure?

“Operational Restructuring” and “Full Year 2025 Revenue Outlook,” along with a forward-looking statement disclaimer.

Are the materials considered filed or furnished?

The information in Items 2.02 and 7.01, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act.

Where can I find LAB’s press release?

It is included as Exhibit 99.1 to the 8-K.

What is the event date for this 8-K?

The earliest event date is November 4, 2025.